Text Size

New Strategies for Non-Invasive Detection of Chronic Allograft Nephropathy

This study has been completed.
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by:
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
NCT00283348
First received: January 25, 2006
Last updated: March 19, 2009
Last verified: March 2009
History of Changes
  Purpose

The purpose of this study is to help researchers find out more about a condition called "Chronic Allograft Nephropathy" (CAN). CAN is a complication that sometimes occurs after kidney transplantation and affects the function of the transplanted kidney. It is hoped that by studying blood, urine, and tissue samples of kidney transplant patients, new ways of diagnosing and treating CAN may be found.


Condition
Chronic Rejection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: New Strategies for Non-Invasive Detection of Chronic Allograft Nephropathy

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Virginia Commonwealth University:

Biospecimen Retention:   Samples With DNA

Blood, Urine


Enrollment: 121
Study Start Date: January 2006
Study Completion Date: December 2008
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients Diagnosis of Chronic Allograft Nephropathy at VCUHS Clinic

Criteria

Inclusion Criteria:

  • Received primary kidney transplant Diagnosis of Chronic Allograft Nephropathy Stable immunosuppression for one month prior to entry

Exclusion Criteria:

  • Serious comorbidity Pregnancy Retransplantation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00283348

Locations
United States, Virginia
VCU Health System
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Virginia Commonwealth University
Hoffmann-La Roche
Investigators
Principal Investigator: Daniel G Maluf, MD Virginia Commonwealth University
Principal Investigator: Valeria Mas, Ph.D. Virginia Commonwealth University
  More Information

No publications provided

Responsible Party: Daniel Maluf, MD, Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT00283348     History of Changes
Other Study ID Numbers: Cell 500
Study First Received: January 25, 2006
Last Updated: March 19, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Virginia Commonwealth University:
Renal Transplantation
Immunosuppression
Chronic Rejection

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on May 23, 2013